NIA-AA Symposium
ENABLING PRECISION MEDICINE FOR ALZHEIMER’S DISEASE
THROUGH OPEN SCIENCE

On-Demand Prerecorded Presentations Available: July 27, 2020 at 12:01 a.m. Central Time
Live Symposium Discussion: July 31, 2020 at 8:30 a.m. Central Time

Meeting Objectives:
This symposium will feature an array of translational research programs that integrate computational and experimental approaches to

1) Discover novel, disease-relevant targets and biomarkers.
2) Develop next-generation animal models and target enabling tools.
3) Support the development of new candidate therapeutics for a diverse portfolio of targets.
4) Advance data-driven drug repositioning and combination therapy development.

The featured programs will include:

- Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD) Target Discovery Program and Affiliated Consortia
- Alzheimer’s Gut Microbiome Project
- MODEL-AD Consortium
- TREAT-AD Consortium
- Translational Bioinformatics Program for Drug Repositioning and Combination Therapy Development
- Alzheimer’s Drug Development Program (ADDP)
- Alzheimer’s Clinical Trials Consortium (ACTC)

Intended Audience: Academic, biotech and pharmaceutical industry researchers with interest in target and biomarker discovery, preclinical and clinical drug development; computational biologists; data scientists; and open science advocates.
PRERECORDED SYMPOSIUM AGENDA

30 minutes  Welcome and Introduction
Suzana Petanceska, National Institute on Aging
Laurie Ryan, National Institute on Aging

2.5 hours  Session 1: AMP-AD and Affiliated Consortia: Precision Medicine Approach to Novel Target and Biomarker Discovery
Co-chairs: Anna Greenwood (Sage Bionetworks) and Vilas Mennon (Columbia University)

Nick Seyfried (Emory University)
Title TBD

Minerva Carrasquillo (Mayo Clinic)
Title TBD

Matthias Arnold (Duke University/Helmholtz University)
Title TBD

Emrin Horgusluoglu-Moloch (Icahn Institute at Mount Sinai School of Medicine)
Title TBD

Catherine Kaczorowski (Jackson Labs)
Title TBD

Ben Readhead (Arizona State University)
Title TBD

2 hours  Session 2: MODEL-AD Consortium
Co-chairs: Andrea Tenner (UCI) and Bruce Lamb (Indiana University)

Ali Mortazavi (UCI)
Title TBD

Grant McGregor (UCI)
Title TBD

Michael Sasner (Jackson Labs)
Title TBD

Greg Carter (Jackson Labs)
Title TBD

Stacey Rizzo (University of Pittsburgh)
Title TBD

Paul Territo (Indiana University)
Title TBD

Lorenzo Refolo (National Institute on Aging)
Title TBD
1.5 hours  **Session 3: TREAT-AD Consortium: Accelerating Drug Discovery for Novel Targets Through Open Science**  
Co-chairs: Lara Mangravite (Sage Bionetworks) and Al Palkowitz (Indiana University)

**Al Palkowitz (Indiana University)**  
Title TBD

**Lara Mangravite (Sage Bionetworks)**  
Title TBD

**Opher Gileadi (Structural Genomic Consortium/Oxford University)**  
Title TBD

**Ben Logsdon (Sage Bionetworks)**  
Title TBD

1.5 hours  **Session 4: Translational Bioinformatics for Drug Repositioning and Combination Therapy Development**  
Co-chairs: Rong Xu (Case Western Reserve University) and Jean Yuan (NIA)

**Claes Wahlestedt (University of Miami)**  
Title TBD

**Marina Sirota (UCSF)**  
Title TBD

**Stephen Wong (Houston Methodist Weill Cornell Medical College)**  
Title TBD

**Olivier Lichtarge (Baylor College of Medicine)**  
Title TBD

2 hours  **Session 5: Alzheimer’s Clinical Trials Infrastructure and Next Generation Candidate Therapeutics**  
Co-chairs: Laurie Ryan, (NIA) and Robbie Brinton (University of Arizona)

**Mark Gurney (Tetra Therapeutics)**  
Title TBD

**Judith Kelleher (Neuronascent Inc.)**  
Title TBD

**Robbie Brinton (University of Arizona)**  
Title TBD

**Frank Longo (Pharmatrophiex)**  
Title TBD

**Linda Van Eldik (Sanders-Brown Center on Aging, University of Kentucky)**  
Title TBD
Susan Catalano (Cognition Therapeutics)
Title TBD